BAVA:CPH
Bavarian Nordic A/S
237,40 DKK
arrow_upward
+0,17%(+0,40) 1d
19 d’oct., 17:00:00 GMT+2 · DKK
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a BAVA...
Obre
236,80 DKK
Alt
239,00 DKK
Baix
234,80 DKK
Capitalització borsària
18,79 kM
Volum mitjà
181,89 k
Volum
105,40 k
Alt 52 setmanes
239,00 DKK
Baix 52 setmanes
234,80 DKK
Accions en circulació
79,27 M
Nombre d'empleats
2 k
Obre
236,80 DKK
Alt
239,00 DKK
Baix
234,80 DKK
Capitalització borsària
18,79 kM
Volum mitjà
181,89 k
Volum
105,40 k
Alt 52 setmanes
239,00 DKK
Baix 52 setmanes
234,80 DKK
Accions en circulació
79,27 M
Nombre d'empleats
2 k
Notícies
De fonts web i partners de notícies
StreetInsider
·
fa 18 hores
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Perfil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Sobre Bavarian Nordic A/S
Conseller delegatPaul Chaplin
Empleats1,91 k
Fundació1 de jul. 1992
Seu principal-
Sector-
Lloc webbavarian-nordic.com